CE marking is the visible sign that a product – in particular a medical device or in-vitro diagnostic – meets the relevant requirements of EU law and may be placed on the market within the European Economic Area. For manufacturers, CE marking is the endpoint of a formal conformity assessment procedure; for authorities, notified bodies, users and patients, it is an indication of compliance with essential safety and performance requirements. In practice, CE marking is closely linked to technical documentation, the quality management system, clinical evaluation and post-market surveillance.
It is important to note: CE marking is not a “quality seal” in a marketing-driven sense, but a legally defined declaration of conformity. Which evidence is required depends, among other things, on the risk class, the intended purpose, the technology, and whether a notified body must be involved. For sponsors, CROs and medical writers, CE marking is relevant because it affects requirements for clinical data, evidence generation and regulatory documentation.
For project planning and budgeting, CE marking is also important: depending on the class, audit cycles, review loops with the notified body, and the preparation of clinical documents determine time-to-market. Those who define a clear evidence and documentation strategy early avoid subsequent rework loops, for example when claims, intended purpose and clinical data are not consistent.
What CE marking means legally
By affixing the CE mark, the manufacturer declares that the product meets the applicable EU legal acts. For medical devices, this is in particular the Medical Device Regulation (MDR) (EU) 2017/745; for in-vitro diagnostics, the IVDR (EU) 2017/746. The declaration is based on a conformity assessment procedure that, depending on the product class, involves assessment by a notified body or can be carried out as self-certification (e.g. for certain lower-class products, where permitted).
CE marking is also linked to responsibility for ongoing compliance management: changes to the product, new safety information, or findings from post-market surveillance can trigger an update of the technical documentation or even a renewed assessment. CE marking does not apply “forever” but is embedded in a system of certificate validity periods, audits and surveillance.
Conformity assessment: process and typical evidence
The procedure begins with classification and the precise definition of the intended purpose. From this, the applicable conformity assessment routes are derived. Typical evidence packages include: the technical dossier, risk management (e.g. according to ISO 14971), usability engineering, performance and safety evidence, and – for many products – clinical data. For MDR products, the clinical evaluation is a central component; it can be based on clinical investigations, literature data, or an equivalence argument, whereby the requirements for equivalence under the MDR are considerably stricter than before.
A common practical mistake is integrating clinical and regulatory evidence too late. If, for example, endpoints or the target population in clinical studies do not match the intended purpose, a gap in the evidence arises. An early strategy in which Regulatory Affairs, clinical development, biometrics and medical writing are aligned pays off here.
Role of the notified body and certificates
For most higher-class medical devices and for many IVDs, a notified body must be involved in the conformity assessment. The notified body reviews, among other things, the quality management system, the technical documentation, and – depending on the route – the clinical evidence. The result is typically a certificate (e.g. EU QMS certificate, EU product certificate). Where CE marking involves a notified body in these cases, the four-digit identification number of the notified body is frequently affixed alongside the CE mark.
Notified bodies work according to defined assessment and audit cycles. Manufacturers must therefore be procedurally proficient in change control, CAPA management and the maintenance of technical documentation. For CROs, it may be relevant that clinical investigations under the MDR are subject to particular requirements for study planning, ethics approval, regulatory communication and vigilance.
Post-market surveillance, vigilance and “living” compliance
CE marking is closely linked to post-market surveillance. Manufacturers must operate a PMS system, regularly prepare reports (e.g. PSUR depending on the class), and assess signals from complaint management, trend analyses and clinical follow-up. In the case of safety-relevant incidents, reporting obligations under vigilance apply. For many products, Post-Market Clinical Follow-up is also expected in order to gather long-term data and update the clinical evaluation.
In practice, PMS is often the area in which audits find weaknesses: incomplete trend analyses, unclear responsibilities, or missing feedback into risk management and the clinical evaluation. A robust system can not only safeguard compliance but also steer product improvements on a data-driven basis.
FAQ
Is CE marking a regulatory “authorisation”?
No. CE marking is a manufacturer’s declaration of conformity based on applicable EU rules. For many products, a notified body is involved, but it is not a central regulatory authorisation as is the case for medicinal products.
When does a notified body number appear alongside the CE mark?
When the conformity assessment involves a notified body, its identification number is generally shown alongside the CE mark. Where self-certification is permitted, the identification number is omitted.
Which documents are particularly critical for CE marking?
Critical elements are a clear intended purpose, consistent technical documentation, robust risk management, and – depending on the product – clinical performance and safety data. Equally important is a functioning PMS and vigilance system for the period after placing on the market.
Regulatory references (selection)
- Regulation (EU) 2017/745 (MDR) – requirements for medical devices on the EU market
- Regulation (EU) 2017/746 (IVDR) – requirements for in-vitro diagnostics
- MDCG guidance on the implementation of conformity assessment, clinical evaluation and PMS in the MDR/IVDR context